Cancer History, Health Insurance Coverage, and Cost-Related Medication Nonadherence and Medication Cost-Coping Strategies in the United States
- PMID: 31277821
- DOI: 10.1016/j.jval.2019.01.015
Cancer History, Health Insurance Coverage, and Cost-Related Medication Nonadherence and Medication Cost-Coping Strategies in the United States
Abstract
Objectives: To evaluate the relationship between cancer history and cost-related medication nonadherence (CRN) as well as cost-coping strategies, by health insurance coverage.
Methods: We used the 2013 to 2016 National Health Interview Survey to identify adults aged 18 to 64 years with (n = 3599) and without (n = 56 909) a cancer history. Cost-related changes in medication use included (1) CRN, measured as skipping, taking less, or delaying medication because of cost, and (2) cost-coping strategies, measured as requesting lower cost medication or using alternative therapies to save money. Separate multivariable logistic regressions were used to calculate the adjusted odds ratios (AORs) of CRN and cost-coping strategies associated with cancer history, stratified by insurance.
Results: Cancer survivors were more likely than adults without a cancer history to report CRN (AOR 1.26; 95% confidence interval [CI] 1.10-1.43) and cost-coping strategies (AOR 1.10; 95% CI 0.99-1.19). Among the privately insured, the difference in CRN by cancer history was the greatest among those enrolled in high-deductible health plans (HDHPs) without health savings accounts (HSAs) (AOR 1.78; 95% CI 1.30-2.44). Among adults with HDHP and HSA, cancer survivors were less likely to report cost-coping strategies (AOR 0.62; 95% CI 0.42-0.90). Regardless of cancer history, CRN and cost-coping strategies were the highest for those uninsured, enrolled in HDHP without HSA, and without prescription drug coverage under their health plan (all P<.001).
Conclusions: Cancer survivors are prone to CRN and more likely to use cost-coping strategies. Expanding options for health insurance coverage, use of HSAs for those with HDHP, and enhanced prescription drug coverage may effectively address CRN.
Keywords: National Health Interview Survey; cancer; cost-coping strategies; cost-related medication nonadherence; health insurance; health saving accounts; high-deductible health plan; medications; out-of-pocket costs.
Copyright © 2019 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.
Similar articles
-
High-Deductible Health Plans and Cancer Survivorship: What Is the Association With Access to Care and Hospital Emergency Department Use?J Oncol Pract. 2019 Nov;15(11):e957-e968. doi: 10.1200/JOP.18.00699. Epub 2019 Aug 8. J Oncol Pract. 2019. PMID: 31393809
-
Recent Trends in Cost-Related Medication Nonadherence Among Cancer Survivors in the United States.J Manag Care Spec Pharm. 2018 Jan;24(1):56-64. doi: 10.18553/jmcp.2018.24.1.56. J Manag Care Spec Pharm. 2018. PMID: 29290172 Free PMC article.
-
Association Between High Deductible Health Plans and Cost-Related Non-adherence to Medications Among Americans with Diabetes: an Observational Study.J Gen Intern Med. 2022 Jun;37(8):1910-1916. doi: 10.1007/s11606-021-06937-9. Epub 2021 Jul 29. J Gen Intern Med. 2022. PMID: 34324130 Free PMC article.
-
Original Research: The Relationship Between Food Insecurity and Cost-Related Medication Nonadherence in Older Adults: A Systematic Review.Am J Nurs. 2020 Jun;120(6):24-36. doi: 10.1097/01.NAJ.0000668732.28490.c1. Am J Nurs. 2020. PMID: 32443122
-
Trends in the 2012 Eisai Oncology Digest: insurance and cost obstacles in cancer treatment.Am J Manag Care. 2012 Dec;18(5 Spec No.):SP222-3. Am J Manag Care. 2012. PMID: 23301711 Review. No abstract available.
Cited by
-
Development and Validation of Subjective Financial Distress Questionnaire (SFDQ): A Patient Reported Outcome Measure for Assessment of Financial Toxicity Among Radiation Oncology Patients.Front Oncol. 2022 Feb 2;11:819313. doi: 10.3389/fonc.2021.819313. eCollection 2021. Front Oncol. 2022. PMID: 35186720 Free PMC article.
-
Shared burden: the association between cancer diagnosis, financial toxicity, and healthcare cost-related coping mechanisms by family members of non-elderly patients in the USA.Support Care Cancer. 2022 Nov;30(11):8905-8917. doi: 10.1007/s00520-022-07234-9. Epub 2022 Jul 25. Support Care Cancer. 2022. PMID: 35877007
-
Guaranteed Income and Financial Treatment Trial (GIFT Trial or GIFTT): a 12-month, randomized controlled trial to compare the effectiveness of monthly unconditional cash transfers to treatment as usual in reducing financial toxicity in people with cancer who have low incomes.Front Psychol. 2023 May 18;14:1179320. doi: 10.3389/fpsyg.2023.1179320. eCollection 2023. Front Psychol. 2023. PMID: 37275728 Free PMC article.
-
Mortality-to-incidence ratios by US Congressional District: Implications for epidemiologic, dissemination and implementation research, and public health policy.Prev Med. 2019 Dec;129S:105849. doi: 10.1016/j.ypmed.2019.105849. Epub 2019 Nov 1. Prev Med. 2019. PMID: 31679842 Free PMC article.
-
High-Deductible Health Plans and Out-of-Pocket Health Care Costs Among Younger Patients With Multiple Myeloma.JCO Oncol Pract. 2025 May 12:OP2400978. doi: 10.1200/OP-24-00978. Online ahead of print. JCO Oncol Pract. 2025. PMID: 40354593
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous